$RMD
RESMED INC Stock $rmd

$rmd Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000094381924000003 Filed on January 25, 2024

Income Statement

Concept	2024 Q1	2023 Q4
Revenue	$1.197B	$1.163B
YoY Change	7.17%	12.48%
Cost Of Revenue	$504.2M	$515.9M
YoY Change	1.01%	13.62%
Gross Profit	$692.8M	$646.9M
YoY Change	12.15%	11.6%
Gross Profit Margin	57.88%	55.64%
Selling, General & Admin	$229.9M	$222.2M
YoY Change	0.64%	4.95%
% of Gross Profit	33.19%	34.34%
Research & Development	$77.07M	$73.88M
YoY Change	0.83%	5.73%
% of Gross Profit	11.13%	11.42%
Depreciation & Amortization	$43.47M	$44.78M
YoY Change	-1.99%	18.58%
% of Gross Profit	6.28%	6.92%
Operating Expenses	$318.2M	$371.8M
YoY Change	0.35%	24.14%
Operating Profit	$374.6M	$275.1M
YoY Change	24.58%	-1.82%
Interest Expense	$3.333M	-$14.95M
YoY Change	-138.18%	211.8%
% of Operating Profit	0.89%	-5.44%
Other Income/Expense, Net	-$2.496M	-$15.64M
YoY Change	-77.9%	140.5%
Pretax Income	$375.4M	$259.5M
YoY Change	29.73%	-5.2%
Income Tax	$74.93M	$50.65M
% Of Pretax Income	19.96%	19.52%
Net Earnings	$300.5M	$208.8M
YoY Change	29.24%	-7.16%
Net Earnings / Revenue	25.1%	17.96%
Basic Earnings Per Share	$2.04	$1.42
Diluted Earnings Per Share	$2.04	$1.42
COMMON SHARES
Basic Shares Outstanding	147.1M shares	147.1M shares
Diluted Shares Outstanding	147.5M shares	147.5M shares

Balance Sheet

Concept	2024 Q1	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$237.9M	$210.2M
YoY Change	4.4%	-16.96%
Cash & Equivalents	$237.9M	$210.2M
Short-Term Investments
Other Short-Term Assets	$466.7M	$179.6M
YoY Change	200.13%	21.83%
Inventory	$829.5M	$933.2M
Prepaid Expenses
Receivables	$817.2M	$729.7M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$2.351B	$2.378B
YoY Change	0.58%	2.28%
LONG-TERM ASSETS
Property, Plant & Equipment	$686.8M	$551.7M
YoY Change	29.89%	5.55%
Goodwill	$2.836B	$2.862B
YoY Change	1.88%	3.42%
Intangibles
YoY Change
Long-Term Investments	$65.11M	$66.09M
YoY Change	-3.81%	3.1%
Other Assets	$363.2M	$275.8M
YoY Change	34.08%	6.02%
Total Long-Term Assets	$4.463B	$4.527B
YoY Change	1.99%	4.05%
TOTAL ASSETS
Total Short-Term Assets	$2.351B	$2.378B
Total Long-Term Assets	$4.463B	$4.527B
Total Assets	$6.815B	$6.905B
YoY Change	1.5%	3.43%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$177.4M	$202.4M
YoY Change	9.6%	3.26%
Accrued Expenses	$380.3M	$332.1M
YoY Change	9.47%	6.4%
Deferred Revenue	$150.8M	$148.9M
YoY Change	6.88%	11.19%
Short-Term Debt	$0.00	$9.898M
YoY Change	-100.0%	-0.02%
Long-Term Debt Due	$9.903M	$9.898M
YoY Change	0.02%	-0.02%
Total Short-Term Liabilities	$773.0M	$764.1M
YoY Change	1.49%	4.28%
LONG-TERM LIABILITIES
Long-Term Debt	$997.0M	$1.217B
YoY Change	-36.73%	-32.05%
Other Long-Term Liabilities	$328.0M	$72.89M
YoY Change	371.58%	44.05%
Total Long-Term Liabilities	$1.325B	$1.659B
YoY Change	-34.39%	-24.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$773.0M	$764.1M
Total Long-Term Liabilities	$1.325B	$1.659B
Total Liabilities	$2.185B	$2.423B
YoY Change	-21.45%	-17.52%
SHAREHOLDERS EQUITY
Retained Earnings	$4.770B	$4.540B
YoY Change	16.68%	15.81%
Common Stock	$1.848B	$1.823B
YoY Change	6.88%	6.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$4.630B	$4.482B
YoY Change
Total Liabilities & Shareholders Equity	$6.815B	$6.905B
YoY Change	1.5%	3.43%

Cashflow Statement

Concept	2024 Q1	2023 Q4
OPERATING ACTIVITIES
Net Income	$300.5M	$208.8M
YoY Change	29.24%	-7.16%
Depreciation, Depletion And Amortization	$43.47M	$44.78M
YoY Change	-1.99%	18.58%
Cash From Operating Activities	$402.0M	$272.8M
YoY Change	42.28%	112.1%
INVESTING ACTIVITIES
Capital Expenditures	$23.11M	$24.56M
YoY Change	-25.99%	-177.55%
Acquisitions
YoY Change
Other Investing Activities	-$10.04M	-$16.58M
YoY Change	-421.89%	-98.33%
Cash From Investing Activities	-$33.15M	-$41.14M
YoY Change	17.96%	-95.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-335.9M	-239.0M
YoY Change	20.16%	-125.61%
NET CHANGE
Cash From Operating Activities	402.0M	272.8M
Cash From Investing Activities	-33.15M	-41.14M
Cash From Financing Activities	-335.9M	-239.0M
Net Change In Cash	32.96M	-7.269M
YoY Change	-231.36%	-120.69%
FREE CASH FLOW
Cash From Operating Activities	$402.0M	$272.8M
Capital Expenditures	$23.11M	$24.56M
Free Cash Flow	$378.9M	$248.3M
YoY Change	50.76%	54.88%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q2	us-gaap	Derivative Asset Current Statement Of Financial Position Extensible Enumeration DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2023Q4	us-gaap	Derivative Asset Current Statement Of Financial Position Extensible Enumeration DerivativeAssetCurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#PrepaidExpenseAndOtherAssetsCurrent
CY2023Q4	us-gaap	Derivative Asset Noncurrent Statement Of Financial Position Extensible Enumeration DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q2	us-gaap	Derivative Asset Noncurrent Statement Of Financial Position Extensible Enumeration DerivativeAssetNoncurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Derivative Liability Noncurrent Statement Of Financial Position Extensible Enumeration DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q2	us-gaap	Derivative Liability Noncurrent Statement Of Financial Position Extensible Enumeration DerivativeLiabilityNoncurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q2	us-gaap	Derivative Liability Current Statement Of Financial Position Extensible Enumeration DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q4	us-gaap	Derivative Liability Current Statement Of Financial Position Extensible Enumeration DerivativeLiabilityCurrentStatementOfFinancialPositionExtensibleEnumeration	http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	3360751000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2610000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-59000	usd
CY2022Q3	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	16919000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-93381000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	210478000	usd
CY2022Q3	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.44
CY2022Q3	us-gaap	Dividends Dividends	64431000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	3432887000	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5120000	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-29654000	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	16936000	usd
	us-gaap	Net Income Loss NetIncomeLoss	428222000	usd
	us-gaap	Net Income Loss NetIncomeLoss	435392000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	17094000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	15533000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	38350000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	33383000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3156000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4853000	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	-2491000	usd
	us-gaap	Debt And Equity Securities Unrealized Gain Loss DebtAndEquitySecuritiesUnrealizedGainLoss	5088000	usd
	rmd	Non Cash Restructuring Expenses NonCashRestructuringExpenses	33239000	usd
	rmd	Non Cash Restructuring Expenses NonCashRestructuringExpenses	0	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	20269000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	75823000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-77095000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	233116000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	74590000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	66646000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-35391000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-9230000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	559115000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	173298000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	53388000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	56406000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	12036000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7636000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	110688000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1011225000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	7305000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	17132000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	250000	usd
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	usd
	us-gaap	Payments For Proceeds From Derivative Instrument Investing Activities PaymentsForProceedsFromDerivativeInstrumentInvestingActivities	6956000	usd
	us-gaap	Payments For Proceeds From Derivative Instrument Investing Activities PaymentsForProceedsFromDerivativeInstrumentInvestingActivities	-7181000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-190123000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1085218000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	20507000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	24666000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	50007000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	8022000	usd
	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	29713000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1293000	usd
	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	0	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	105000000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	1070000000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	315000000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	45000000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	141275000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	128931000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-390090000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	891022000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3454000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	387000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17644000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-20511000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	227891000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	273710000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	210247000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	253199000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	173437000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	107985000	usd
	us-gaap	Interest Paid Net InterestPaidNet	28762000	usd
	us-gaap	Interest Paid Net InterestPaidNet	17472000	usd
	rmd	Noncash Part Of Acquisition Fair Value Of Assets Acquired NoncashPartOfAcquisitionFairValueOfAssetsAcquired	38520000	usd
	rmd	Noncash Part Of Acquisition Fair Value Of Assets Acquired NoncashPartOfAcquisitionFairValueOfAssetsAcquired	359730000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	5401000	usd
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Liabilities Assumed1 NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1	144778000	usd
	rmd	Goodwill Acquired During Period Increase Decrease GoodwillAcquiredDuringPeriodIncreaseDecrease	77712000	usd
	rmd	Goodwill Acquired During Period Increase Decrease GoodwillAcquiredDuringPeriodIncreaseDecrease	800003000	usd
	rmd	Deferred Payment Obligations For Acquisitions DeferredPaymentObligationsForAcquisitions	143000	usd
	rmd	Deferred Payment Obligations For Acquisitions DeferredPaymentObligationsForAcquisitions	874000	usd
	rmd	Business Acquisition Contingent Consideration Recognized Liability BusinessAcquisitionContingentConsiderationRecognizedLiability	-1293000	usd
	rmd	Business Acquisition Contingent Consideration Recognized Liability BusinessAcquisitionContingentConsiderationRecognizedLiability	2856000	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	111981000	usd
	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	1011225000	usd
CY2023Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1162801000	usd
CY2022Q4	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1033744000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
CY2023Q4	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	23100000	usd
	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	45700000	usd
CY2022Q4	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	20400000	usd
	us-gaap	Operating Lease Lease Income OperatingLeaseLeaseIncome	44100000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2	segment
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2265122000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1984038000	usd
CY2023Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	44784000	usd
CY2022Q4	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	37767000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	89718000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	74040000	usd
CY2023Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	467223000	usd
CY2023Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	459126000	usd
CY2023Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	2942000	usd
CY2023Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	3956000	usd
CY2023Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	463049000	usd
CY2023Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	534930000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	933214000	usd
CY2023Q2	us-gaap	Inventory Net InventoryNet	998012000	usd
CY2023Q4	us-gaap	Prepaid Taxes PrepaidTaxes	128649000	usd
CY2023Q2	us-gaap	Prepaid Taxes PrepaidTaxes	114009000	usd
CY2023Q4	rmd	Prepaid Inventory PrepaidInventory	196595000	usd
CY2023Q2	rmd	Prepaid Inventory PrepaidInventory	143084000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	179632000	usd
CY2023Q2	us-gaap	Other Assets Current OtherAssetsCurrent	179925000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	504876000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	437018000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1266106000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1205868000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	714372000	usd
CY2023Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	668012000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	551734000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	537856000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	528178000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	552341000	usd
CY2023Q2	us-gaap	Goodwill Goodwill	2770299000	usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	77712000	usd
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	13843000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	2861854000	usd
CY2023Q4	rmd	Marketable Equity Investments Fair Value MarketableEquityInvestmentsFairValue	7617000	usd
CY2023Q2	rmd	Marketable Equity Investments Fair Value MarketableEquityInvestmentsFairValue	12423000	usd
CY2023Q4	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	74993000	usd
CY2023Q2	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	68748000	usd
CY2023Q4	us-gaap	Equity Method Investments EquityMethodInvestments	66088000	usd
CY2023Q2	us-gaap	Equity Method Investments EquityMethodInvestments	65366000	usd
CY2023Q4	rmd	Equity Investments Total By Measurement Category EquityInvestmentsTotalByMeasurementCategory	148698000	usd
CY2023Q2	rmd	Equity Investments Total By Measurement Category EquityInvestmentsTotalByMeasurementCategory	146537000	usd
CY2023Q2	rmd	Equity Investments EquityInvestments	146537000	usd
	rmd	Additional Equity Investments AdditionalEquityInvestments	7305000	usd
	rmd	Observable Price Adjustments On Non Marketable Equity Securities ObservablePriceAdjustmentsOnNonMarketableEquitySecurities	2315000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-4806000	usd
	us-gaap	Payments For Proceeds From Investments PaymentsForProceedsFromInvestments	-250000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-3156000	usd
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	753000	usd
CY2023Q4	rmd	Equity Investments EquityInvestments	148698000	usd
CY2022Q2	rmd	Equity Investments EquityInvestments	58375000	usd
	rmd	Additional Equity Investments AdditionalEquityInvestments	74365000	usd
	rmd	Observable Price Adjustments On Non Marketable Equity Securities ObservablePriceAdjustmentsOnNonMarketableEquitySecurities	9275000	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-4187000	usd
	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-4853000	usd
	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	1801000	usd
CY2022Q4	rmd	Equity Investments EquityInvestments	134776000	usd
CY2023Q4	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-1900000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-2500000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	8400000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	5100000	usd
CY2023Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	27621000	usd
CY2022Q2	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	25889000	usd
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	10448000	usd
	us-gaap	Product Warranty Accrual Warranties Issued ProductWarrantyAccrualWarrantiesIssued	5099000	usd
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	7745000	usd
	us-gaap	Product Warranty Accrual Payments ProductWarrantyAccrualPayments	5480000	usd
	us-gaap	Standard And Extended Product Warranty Accrual Foreign Currency Translation Gain Loss StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss	-716000	usd
	us-gaap	Standard And Extended Product Warranty Accrual Foreign Currency Translation Gain Loss StandardAndExtendedProductWarrantyAccrualForeignCurrencyTranslationGainLoss	-281000	usd
CY2023Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	31040000	usd
CY2022Q4	us-gaap	Product Warranty Accrual ProductWarrantyAccrual	25789000	usd
CY2023Q4	rmd	Short Term Debt Gross ShortTermDebtGross	10000000	usd
CY2023Q2	rmd	Short Term Debt Gross ShortTermDebtGross	10000000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	102000	usd
CY2023Q2	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	98000	usd
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	9898000	usd
CY2023Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	9902000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1220000000	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1435000000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	3231000	usd
CY2023Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	3766000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	1216769000	usd
CY2023Q2	us-gaap	Long Term Debt LongTermDebt	1431234000	usd
CY2023Q4	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	1226667000	usd
CY2023Q2	us-gaap	Debt Longterm And Shortterm Combined Amount DebtLongtermAndShorttermCombinedAmount	1441136000	usd
	rmd	Debt To Consolidated Ebitda Ratio DebtToConsolidatedEbitdaRatio	3.50
	rmd	Line Of Credit Facility Collateral Percentage Of Company LineOfCreditFacilityCollateralPercentageOfCompany	0.10
CY2023Q4	us-gaap	Senior Notes SeniorNotes	500000000	usd
CY2023Q2	us-gaap	Senior Notes SeniorNotes	500000000	usd
CY2023Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	663485000	shares
CY2022Q4	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	293796000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	643466000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	270100000	shares
CY2023Q4	us-gaap	Net Income Loss NetIncomeLoss	208800000	usd
CY2022Q4	us-gaap	Net Income Loss NetIncomeLoss	224914000	usd
	us-gaap	Net Income Loss NetIncomeLoss	428222000	usd
	us-gaap	Net Income Loss NetIncomeLoss	435392000	usd
CY2023Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	147132000	shares
CY2022Q4	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146704000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	147104000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	146568000	shares
CY2023Q4	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	413000	shares
CY2022Q4	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	701000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	468000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	799000	shares
CY2023Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	147545000	shares
CY2022Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	147405000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	147572000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	147367000	shares
CY2023Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.42
CY2022Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.53
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.91
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.97
CY2023Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.42
CY2022Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.53
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.95
CY2022Q2	rmd	Number Of Patents NumberOfPatents	8	patent
CY2023Q1	rmd	Number Of Patents NumberOfPatents	3	patent
	rmd	Receivables Sold With Limited Recourse ReceivablesSoldWithLimitedRecourse	97500000	usd
	rmd	Receivables Sold With Limited Recourse ReceivablesSoldWithLimitedRecourse	84300000	usd
CY2023Q4	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	29200000	usd
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	800000	usd
CY2023Q2	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	32600000	usd
CY2023	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	600000	usd
CY2023Q4	us-gaap	Derivative Assets DerivativeAssets	21374000	usd
CY2023Q2	us-gaap	Derivative Assets DerivativeAssets	2405000	usd
CY2023Q4	us-gaap	Derivative Liabilities DerivativeLiabilities	72613000	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	70699000	usd

Files In Submission

Name	View Source	Status
rmd-20231231_cal.xml	Edgar Link	unprocessable
rmd-20231231_lab.xml	Edgar Link	unprocessable
rmd-20231231_def.xml	Edgar Link	unprocessable
rmd-20231231_pre.xml	Edgar Link	unprocessable
0000943819-24-000003-index-headers.html	Edgar Link	pending
0000943819-24-000003-index.html	Edgar Link	pending
0000943819-24-000003.txt	Edgar Link	pending
0000943819-24-000003-xbrl.zip	Edgar Link	pending
ex101-formofpsuagreementfo.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rmd-20231231.htm	Edgar Link	pending
rmd-20231231.xsd	Edgar Link	pending
rmd-20231231xex311.htm	Edgar Link	pending
rmd-20231231xex312.htm	Edgar Link	pending
rmd-20231231xex32.htm	Edgar Link	pending
Show.js	Edgar Link	pending
rmd-20231231_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$RMD
RESMED INC Stock $rmd

2024 Q1 Form 10-Q Financial Statement

#000094381924000003 Filed on January 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMD RESMED INC Stock $rmd

2024 Q1 Form 10-Q Financial Statement

#000094381924000003 Filed on January 25, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$RMD
RESMED INC Stock $rmd